undamentalytics Newsletter
Sign in

Fate Therapeutics Inc (FATE) stock

Add to watchlist

Add holding +

NASDAQ: FATE Nasdaq Biotechnology Next results ~November 12, 2026

C Fundamentals grade

Fate Therapeutics Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.0

Growth cash-flow model

Base case. Range ~$1.0–$1.0. Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Fate Therapeutics Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 6 sales by directors and officers, last 12 monthsInsider trades
  • Funds90 adding, 65 cuttingOf 30 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Fate Therapeutics files

Where Fate Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $6m, down 23.4% on a year earlier, a smaller fall than the 52.6% decline a quarter earlier. Free-cash-flow margin fell to -1627.2% from -1402.2% a year earlier. Operating margin widened to -2058.1% from -2271.2%. It passes 1 of our 1 financial-health checks.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Fate Therapeutics Inc's trailing-twelve-month revenue fell 23.4% year on year, with a free-cash-flow margin of -1627.2%. Where it stands out: days sales outstanding of 40 days ranks 18 of 100 biotechnology companies we cover. Where it lags: stock pay as % of revenue of 274.8% ranks 155 of 179 biotechnology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 11.1% while net income grew 26.5%: a 15pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 213.1 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 23.4% over the last 12 months.
  • Loss-making. Operating margin is -2058.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -1627.2% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 274.8% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • High sales multiple. The shares trade at 37 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.25 against an average estimate of -$0.26: beat by 2.6%
Revenue
$2m, up 9.2% on a year earlier
Share reaction
-5.5% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.26

Fate Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.4%
  • 1 week-2.4%
  • 1 month-13.4%
  • This year+105.1%
  • 1 year+48.9%
  • 5 years-96.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$6.5M
Operating margin
-2058.1%
Net margin
-1941.1%
EPS (TTM, diluted)
$-1.05

Growth

Revenue growth
−23.4%
Change in growth rate
+29.3 pts
Share count change
+1.2%

Cash

Free cash flow (TTM)
-$106M
FCF margin
-1627.2%
Stock pay % of revenue
274.8%

Earnings

Last results
August 13, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Fate Therapeutics Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Fate Therapeutics Inc as an operating company, with every model that fits that kind of business. Cost of equity 10.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.23 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.0 ~$1.0–$1.0 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.1 ~$0.1–$0.5 Left out: out of range vs price (0.06x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.0 ~$1.0–$1.0 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Fate Therapeutics Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$3.37$2.51$6.11$12.83$19.57$90.93$58.51$10.09$3.74$1.65$0.98$2.01
Market value$86m$80m$257m$721m$1.3bn$7.5bn$5.5bn$977m$368m$188m$116m$241m
+ Net debt (− = net cash)−$43m−$76m−$70m−$172m−$86m−$167m−$134m−$61m−$42m−$36m−$47m−$32m
Enterprise value$43m$4m$187m$549m$1.2bn$7.3bn$5.4bn$916m$326m$152m$70m$208m
Multiples
Price / sales 35.3x18.1x62.5x152.1x125.0xn/m99.3x10.1x5.8x13.8x17.5x37.1x
Price / earnings ————————————
Price / free cash flow ————————————
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Fate Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -37.1% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -931.0%; its worst year was -2271.2%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -745.0% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 32.2% over five years; stock-based pay has been a median 128.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $1m and EPS of −$0.26 (range −$0.28 to −$0.21) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.02 +12% $6m −15%
Next −$0.97 +5% $5m −16%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −2.1% on 90 days ago. In the last 30 days, 4 analysts raised Fate Therapeutics Inc's forecast and 2 cut it.

Consensus EPS forecast Fate Therapeutics Inc, last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.04 Current fiscal year, 60 days ago: −$1.02 Current fiscal year, 30 days ago: −$1.02 Current fiscal year, 7 days ago: −$1.02 Current fiscal year, Now: −$1.02 −$1.02 Next fiscal year, 90 days ago: −$0.99 Next fiscal year, 60 days ago: −$0.97 Next fiscal year, 30 days ago: −$0.97 Next fiscal year, 7 days ago: −$0.97 Next fiscal year, Now: −$0.97 −$0.97

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.04−$0.99
60 days ago −$1.02−$0.97
30 days ago −$1.02−$0.97
7 days ago −$1.02−$0.97
Now −$1.02−$0.97

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.26 −$0.25 +2.6%
Mar 2026 −$0.28 −$0.26 +5.5%
Dec 2025 −$0.27 −$0.27 +0.5%
Sept 2025 −$0.28 −$0.27 +4.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 13, 2026

No numeric guidance in Fate Therapeutics Inc's latest earnings release (filed August 13, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

11 analysts, Oct 2026
Buy545%
Hold655%
Sell00%

Monthly trend

  1. Oct 202614611
  2. Sep 202614611
  3. Aug 202614611
  4. Jul 202615612

Counts of recommendations published by analysts covering Fate Therapeutics Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.0%
of tradable shares
Days to cover
6.6
at average volume
Short interest, 1 month
+13%
to October 15, 2026
Held by institutions
70%
of shares
Held by insiders
1.1%
of shares
Employees
161
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +48.9%

$1.35 on October 31, 2025 to $2.01

ThenNowEffect
Revenue (last 12 months) $8m $6m −23.4%
P/S multiple 18.9x 37.1x +96.6%
Share count 118m 120m −1.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −15.9%

$2.39 on November 3, 2023 to $2.01

ThenNowEffect
Revenue (last 12 months) $119m $6m −94.6%
P/S multiple 2.0x 37.1x +1792.9%
Share count 98m 120m −18.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
FATE−36%−83%−63%−56%−41%+105%
Industry peers (median)−35%−56%−17%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
FATE33%25%33%42%25%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
FATE−59%−84%−85%−81%−64%−42%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 99% from January 14, 2021 to April 3, 2025. Getting back needed a 17165% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.96 – $3.11
From 52-week high
−35.4%
vs 50-day average
−12.0%
vs 200-day average
+2.4%
Volatility (1 year)
89%
Beta vs S&P 500
2.13

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±9.3%
After a week
7 up, 5 down
typical move ±10.8%
After a month
5 up, 7 down
typical move ±13.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −5.5% +0.5% −9.9% −14.0%
May 13, 2026 −15.6% +1.4% −18.2% −8.4%
February 26, 2026 0.0% −1.0% −6.8% −20.9%
November 13, 2025 −7.7% −1.7% −3.8% +7.7%
August 12, 2025 +20.2% +1.4% +21.3% +8.5%
May 13, 2025 −10.3% +0.8% +16.8% +30.8%
March 5, 2025 +9.5% −0.7% +6.3% −28.4%
November 12, 2024 −15.2% −0.3% −14.8% −24.6%
August 13, 2024 −1.8% +2.0% +10.2% +12.3%
May 9, 2024 +10.3% +0.7% +11.9% +4.3%
February 26, 2024 +7.2% −0.2% +1.7% −1.4%
November 8, 2023 −7.8% −0.7% +7.4% −3.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fate Therapeutics Inc in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Fate Therapeutics Inc
$0 $50M $100M $150M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $106.2M Revenue (TTM), FY23 Q4: $63.5M Revenue (TTM), FY24 Q1: $6.5M Revenue (TTM), FY24 Q2: $12.3M Revenue (TTM), FY24 Q3: $13.4M Revenue (TTM), FY24 Q4: $13.6M Revenue (TTM), FY25 Q1: $13.3M Revenue (TTM), FY25 Q2: $8.5M Revenue (TTM), FY25 Q3: $7.1M Revenue (TTM), FY25 Q4: $6.6M Revenue (TTM), FY26 Q1: $6.3M Revenue (TTM), FY26 Q2: $6.5M $6.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $106.2M
FY23 Q4 $63.5M
FY24 Q1 $6.5M
FY24 Q2 $12.3M
FY24 Q3 $13.4M
FY24 Q4 $13.6M
FY25 Q1 $13.3M
FY25 Q2 $8.5M
FY25 Q3 $7.1M
FY25 Q4 $6.6M
FY26 Q1 $6.3M
FY26 Q2 $6.5M
Revenue growth, TTM YoY Fate Therapeutics Inc
-100% 0% 100% 200% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 53.9% Revenue growth, TTM YoY, FY23 Q4: -34.0% Revenue growth, TTM YoY, FY24 Q1: -95.3% Revenue growth, TTM YoY, FY24 Q2: -89.7% Revenue growth, TTM YoY, FY24 Q3: -87.3% Revenue growth, TTM YoY, FY24 Q4: -78.5% Revenue growth, TTM YoY, FY25 Q1: 105.9% Revenue growth, TTM YoY, FY25 Q2: -31.2% Revenue growth, TTM YoY, FY25 Q3: -46.9% Revenue growth, TTM YoY, FY25 Q4: -51.2% Revenue growth, TTM YoY, FY26 Q1: -52.6% Revenue growth, TTM YoY, FY26 Q2: -23.4% -23.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 53.9%
FY23 Q4 -34.0%
FY24 Q1 -95.3%
FY24 Q2 -89.7%
FY24 Q3 -87.3%
FY24 Q4 -78.5%
FY25 Q1 105.9%
FY25 Q2 -31.2%
FY25 Q3 -46.9%
FY25 Q4 -51.2%
FY26 Q1 -52.6%
FY26 Q2 -23.4%
Operating margin (TTM) Fate Therapeutics Inc
-4000% -3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -194.8% Operating margin (TTM), FY23 Q4: -299.9% Operating margin (TTM), FY24 Q1: -3287.9% Operating margin (TTM), FY24 Q2: -1587.3% Operating margin (TTM), FY24 Q3: -1462.1% Operating margin (TTM), FY24 Q4: -1542.6% Operating margin (TTM), FY25 Q1: -1503.5% Operating margin (TTM), FY25 Q2: -2271.2% Operating margin (TTM), FY25 Q3: -2448.2% Operating margin (TTM), FY25 Q4: -2222.4% Operating margin (TTM), FY26 Q1: -2207.5% Operating margin (TTM), FY26 Q2: -2058.1% -2058.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -194.8%
FY23 Q4 -299.9%
FY24 Q1 -3287.9%
FY24 Q2 -1587.3%
FY24 Q3 -1462.1%
FY24 Q4 -1542.6%
FY25 Q1 -1503.5%
FY25 Q2 -2271.2%
FY25 Q3 -2448.2%
FY25 Q4 -2222.4%
FY26 Q1 -2207.5%
FY26 Q2 -2058.1%
FCF margin (TTM) Fate Therapeutics Inc
-3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -172.9% FCF margin (TTM), FY23 Q4: -217.9% FCF margin (TTM), FY24 Q1: -2157.8% FCF margin (TTM), FY24 Q2: -1148.4% FCF margin (TTM), FY24 Q3: -985.5% FCF margin (TTM), FY24 Q4: -906.8% FCF margin (TTM), FY25 Q1: -938.7% FCF margin (TTM), FY25 Q2: -1402.2% FCF margin (TTM), FY25 Q3: -1617.3% FCF margin (TTM), FY25 Q4: -1685.8% FCF margin (TTM), FY26 Q1: -1711.4% FCF margin (TTM), FY26 Q2: -1627.2% -1627.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -172.9%
FY23 Q4 -217.9%
FY24 Q1 -2157.8%
FY24 Q2 -1148.4%
FY24 Q3 -985.5%
FY24 Q4 -906.8%
FY25 Q1 -938.7%
FY25 Q2 -1402.2%
FY25 Q3 -1617.3%
FY25 Q4 -1685.8%
FY26 Q1 -1711.4%
FY26 Q2 -1627.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1 3 1 2 4 4 5 11 31 56 96 64 14 7 6
EBITDA −13 −13 −17 −27 −31 −41 −66 −99 −125 −211 −295 −172 −191 −135 −122
Operating income −13 −14 −18 −28 −32 −42 −67 −101 −128 −217 −308 −191 −210 −148 −134
Net income −13 −14 −21 −30 −33 −43 −67 −98 −173 −212 −282 −161 −186 −136 −126
Diluted EPS −$16.16 −$13.06 −$3.54 −$1.18 −$1.05 −$1.02 −$1.19 −$1.44 −$2.10 −$2.24 −$2.91 −$1.64 −$1.64 −$1.15 −$1.05
Growth (year on year)
Revenue — +128.2% −63.6% +150.4% +81.1% −6.7% +15.4% +125.3% +194.3% +77.7% +72.4% −34.0% −78.5% −51.2% −23.4%
Margins
EBITDA margin <−999% −485.7% <−999% <−999% −706.1% <−999% <−999% −922.6% −397.7% −378.1% −305.9% −271.1% <−999% <−999% <−999%
Operating margin <−999% −507.8% <−999% <−999% −726.1% <−999% <−999% −943.1% −407.5% −388.6% −320.2% −299.9% <−999% <−999% <−999%
Net margin <−999% −533.3% <−999% <−999% −760.2% <−999% <−999% −919.0% −551.6% −379.9% −292.5% −253.3% <−999% <−999% <−999%
Free-cash-flow margin <−999% −523.7% <−999% −818.4% −687.9% −938.7% −864.0% −848.0% −140.5% −382.4% −294.7% −217.9% −906.8% <−999% <−999%
Cash flow
Cash from operations −12 −13 −15 −18 −30 −37 −39 −83 −39 −163 −248 −132 −123 −106 −102
Capital spending 0 1 0 1 0 2 2 7 5 51 36 6 1 6 4
Free cash flow −12 −14 −16 −20 −30 −39 −41 −91 −44 −214 −284 −138 −124 −112 −106
Stock-based pay 0 0 2 2 3 4 6 17 31 54 79 43 41 25 18
Free cash flow after stock pay −12 −14 −17 −22 −33 −42 −47 −108 −75 −268 −363 −182 −165 −137 −123
Balance sheet
Cash 6 9 54 65 89 89 191 100 167 134 61 42 36 47 32
Total debt 0 4 2 22 13 19 18 14 0 0 0 0 0 0 0
Net debt (negative = net cash) −6 −5 −52 −43 −76 −70 −172 −86 −167 −134 −61 −42 −36 −47 −32
Diluted shares — 1m 6m 25m 32m 42m 56m 68m 82m 95m 97m 98m 114m 119m 120m
Returned to shareholders
Buybacks 0 — — — — — — — — — — — — — —
Total returned 0 — — — — — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 1 checks passed · June 30, 2026
What it owns · $260m
Short-term assets $158mLonger-term assets $102m
What it owes, and who funded it · $186m
Short-term liabilities $33mShareholders' equity $153m
  • Short-term assets cover short-term liabilities $158m of assets due within a year against $33m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Fate Therapeutics Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.2%
year over year
R&D spending
1546.0%
of revenue
Days sales outstanding
40 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated FATE HCWB CGON TCRX EVAX ROIV Median
Revenue, last 12 months $6m $7m $6m $7m $8m $8m $56m
Revenue growth, last 12 months −23.4% 700.2% >999% 2.2% 125.1% −67.6% 12.6%
Revenue growth, 3-year average −62.1% 20.4% — −24.3% — −46.4% 13.7%
Revenue growth, latest quarter 9.2% >999% >999% −65.8% — −33.5% 10.2%
Operating margin <−999% −115.3% <−999% <−999% −122.7% <−999% −189.4%
Operating margin, 3-year average <−999% −856.2% <−999% <−999% — −102.3% −363.5%
Net margin <−999% −83.8% <−999% <−999% −102.4% <−999% −169.8%
Cash from operations / revenue <−999% −182.1% <−999% <−999% −88.0% <−999% −168.0%
Free-cash-flow margin <−999% −182.1% <−999% <−999% −88.2% <−999% −162.4%
Free-cash-flow margin, 3-year average <−999% −759.7% — <−999% — <−999% −310.0%
Stock pay / revenue 274.8% 3.4% 567.2% 138.4% 4.1% >999% 20.0%
Change in share count 1.2% −47.7% 14.1% 4.1% 497.3% 0.6% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -23.4% 12.6% 126 of 172
Change in growth rate Growth +29.3pp -0.1pp 35 of 172
Operating margin Profitability -2058.1% -189.4% 146 of 175
Net margin Profitability -1941.1% -157.3% 150 of 180
Free-cash-flow margin Cash generation -1627.2% -145.4% 148 of 176
Stock pay as % of revenue Cash generation 274.8% 19.2% 155 of 179
Change in share count Balance sheet 1.2% 7.9% 39 of 156
Days sales outstanding Balance sheet 40 days 75 days 18 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$194M
Institutions reporting
155
Shares held vs prior quarter
▼ 3.2%
Positions opened / closed
32 / 30

Top buyers and sellers, Q2 2026: 90 institutions bought and 65 sold ; the biggest buyer was Millennium Management LLC (+2.4M shares) and the biggest seller Blackrock, Inc (−2.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Redmile Group, LLC $34.8M 12.9M 18.0% 0.0%
Blackrock, Inc. $19.7M 7.3M 10.2% ▼ 27.5%
Vanguard Portfolio Management LLC $12.3M 4.5M 6.3% ▲ 9.9%
Vanguard Capital Management LLC $12M 4.4M 6.2% ▲ 6.0%
Acadian Asset Management LLC $11.7M 4.4M 6.1% ▲ 5.6%
AQR Capital Management LLC $10.4M 3.8M 5.4% ▲ 27.8%
Two Sigma Investments, LP $9.7M 3.6M 5.0% ▲ 3.6%
Johnson & Johnson $9.1M 3.4M 4.7% 0.0%
Renaissance Technologies LLC $8.1M 3.0M 4.2% ▲ 0.3%
Millennium Management LLC $6.6M 2.4M 3.4% New
Goldman Sachs Group Inc $5.5M 2.0M 2.9% ▲ 54.3%
Geode Capital Management, LLC $3.6M 1.3M 1.8% ▼ 49.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Fate Therapeutics Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $322,863 6 trades by 2 insiders · 0% under pre-set plans
Net ▼ $322,863 net selling
Insider Date Trade Shares Price Value
Valamehr Bahram President and CEO August 4, 2026 Sell 43,947 $2.46 $108,110
Tahl Cindy See Remarks August 4, 2026 Sell 38,800 $2.46 $95,448
Valamehr Bahram President and CEO May 20, 2026 Sell 28,946 $1.88 $54,418
Tahl Cindy See Remarks May 20, 2026 Sell 25,590 $1.88 $48,109
Valamehr Bahram President and CEO January 9, 2026 Sell 5,190 $1.07 $5,553
Tahl Cindy See Remarks January 9, 2026 Sell 10,589 $1.06 $11,224

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Fate Therapeutics Inc disclosed in the last 12 months; 1 earlier trade on record.

  • Daniel S. Goldman(D-NY 10):Sale (full), $1,001 - $15,000, traded January 31, 2023, filed February 24, 2023

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 13, 2026
  • February 26, 2026
  • November 13, 2025
  • August 12, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Fate Therapeutics Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Fate Therapeutics Inc in brief

What does Fate Therapeutics Inc do?
Fate Therapeutics Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Fate Therapeutics Inc's stock ticker?
Fate Therapeutics Inc trades under the ticker FATE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Fate Therapeutics Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Fate Therapeutics Inc reported revenue of $6.5M, 23.4% lower than a year earlier, according to its SEC filings.
What is Fate Therapeutics Inc's free cash flow?
Fate Therapeutics Inc's free-cash-flow margin is -1627.2% of revenue over the trailing twelve months, ranking 148 of the 176 biotechnology companies we cover.
Who are Fate Therapeutics Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Redmile Group, LLC, Blackrock, Inc. and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Fate Therapeutics Inc's market cap?
On November 2, 2026, Fate Therapeutics Inc's market capitalisation was about $241M and net debt of -$32.4M. Market figures come from third-party market data and may be delayed.
Who are Fate Therapeutics Inc's competitors?
In our Biotechnology peer group, the companies closest to Fate Therapeutics Inc are HCW Biologics Inc., CG Oncology, Inc., Tscan Therapeutics, Inc., Evaxion A/s and Roivant Sciences Ltd. The side-by-side comparison below sets their revenue, margins and growth against Fate Therapeutics Inc's.
Are insiders buying or selling Fate Therapeutics Inc stock?
Over the last 12 months, Fate Therapeutics Inc's directors and officers reported 0 open-market purchases and 6 sales on Form 4. The insider trading page charts every trade.
When is Fate Therapeutics Inc's next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Fate Therapeutics Inc announces its own schedule.